GlassScriptPhysician profile
Danielle Don Skaar
NPI 1558383653
$1,073.70
in general payments reported to CMS, 2019-2025
11 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $164 · 2022: $330 · 2023: $204 · 2024: $249 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $361.60 | 2021-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.23 | 2022-2023 | |
| Alkermes, INC. | $103.66 | 2022-2025 | Lybalvi, Aristada |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $101.77 | 2022 | |
| Abbvie INC. | $86.68 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.43 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $66.23 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $47.35 | 2022-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $47.19 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $16.37 | 2023 | Austedo Xr |
| Collegium Pharmaceutical, INC. | $15.19 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Skaar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.